Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
'Burned-out' primary testicular cancer.
Fabre E, Jira H, Izard V, Ferlicot S, Hammoudi Y, Theodore C, Di Palma M, Benoit G, Droupy S. Fabre E, et al. BJU Int. 2004 Jul;94(1):74-8. doi: 10.1111/j.1464-410X.2004.04904.x. BJU Int. 2004. PMID: 15217435
Differential predictive value of resident memory CD8+T cell subpopulations in patients with non-small-cell lung cancer treated by immunotherapy.
Paolini L, Tran T, Corgnac S, Villemin JP, Wislez M, Arrondeau J, Johannes L, Ulmer J, Vieillard LV, Pineau J, Gey A, Quiniou V, Barennes P, Pham HP, Gruel N, Hasan M, Libri V, Mella S, De Percin S, Boudou-Rouquette P, Caidi A, Cremer I, Blons H, Leroy K, Laurent-Puig P, De Saint Basile H, Gibault L, Ravel P, Mami-Chouaib F, Goldwasser F, Fabre E, Damotte D, Tartour E. Paolini L, et al. Among authors: fabre e. J Immunother Cancer. 2024 Dec 3;12(12):e009440. doi: 10.1136/jitc-2024-009440. J Immunother Cancer. 2024. PMID: 39631852 Free PMC article.
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.
Swalduz A, Beau-Faller M, Planchard D, Mazieres J, Bayle-Bleuez S, Debieuvre D, Fallet V, Geier M, Cortot A, Couraud S, Daniel C, Domblides C, Pichon E, Fabre E, Larivé S, Lerolle U, Tomasini P, Wislez M, Missy P, Morin F, Westeel V, Auliac JB. Swalduz A, et al. Among authors: fabre e. Lung Cancer. 2024 Nov 26;199:108038. doi: 10.1016/j.lungcan.2024.108038. Online ahead of print. Lung Cancer. 2024. PMID: 39616778
Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.
Birsen G, Gounant V, Girard N, Cadranel J, Monnet I, Raynaud-Donzel C, Fabre E, Giroux Leprieur E, Leroy K, Damotte D, Alifano M, Arrondeau J, Cremer I, Chapron J, Wislez M. Birsen G, et al. Among authors: fabre e. Transl Lung Cancer Res. 2024 Sep 30;13(9):2212-2221. doi: 10.21037/tlcr-24-263. Epub 2024 Sep 12. Transl Lung Cancer Res. 2024. PMID: 39430330 Free PMC article.
Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 study.
Meyo MT, Boudou-Rouquette P, Arrondeau J, Yu Chen JQ, Hirsch L, Neveux N, Fabre E, Guidet C, Damotte D, Wislez M, Alexandre J, Durand JP, Ulmann G, Goldwasser F. Meyo MT, et al. Among authors: fabre e. Clin Nutr ESPEN. 2024 Dec;64:44-50. doi: 10.1016/j.clnesp.2024.09.002. Epub 2024 Sep 6. Clin Nutr ESPEN. 2024. PMID: 39244156
PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up.
Lailler C, Didelot A, Garinet S, Berthou H, Sroussi M, de Reyniès A, Dedhar S, Martin-Lannerée S, Fabre E, Le Pimpec-Barthes F, Perrier A, Poindessous V, Mansuet-Lupo A, Djouadi F, Launay JM, Laurent-Puig P, Blons H, Mouillet-Richard S. Lailler C, et al. Among authors: fabre e. Oncogene. 2024 Sep;43(37):2781-2794. doi: 10.1038/s41388-024-03130-0. Epub 2024 Aug 15. Oncogene. 2024. PMID: 39147880 Free PMC article.
246 results